Live now banner (2)

8:30 am
Registration and Morning Networking

9:00 am Chairperson’s Opening Remarks

OPTIMIZING THE ROLE OF MEDICAL AFFAIRS IN IMPROVING MARKET ACCESS

9:10 am The Role of Medical Managed Care Teams in Educating Payers on the Value of Gene Therapies to Support Optimal Patient Access

Synopsis

  • Discover how Medical Managed Care Teams are engaging and educating cross-functional payer teams on gene therapy topics
  • Discover how KOL’s are being engaged and educated to support payer interactions
  • Assess the key steps to engaging early adopters and building therapeutic advocates within KOL and payer communities
  • Understand how KOL and payer insights are being gathered and relayed to Market Access teams to ensure realistic and viable proposals are being delivered

9:40 am Identify the Education Programs for Referral Sites that Support Accurate Information Sharing with HCPs to Improve Patient Enrolment

  • Ruth Haile-Meskale Medical Science Liaison Lead, Gene Therapy, Hematology, Spark Therapeutics

Synopsis

  • Unique challenges associated with referring patients to gene therapy protocols
  • Targeted HCP education can enable informed patient referrals to gene therapy protocols

10:10 am
Morning Coffee Break

MAXIMIZING THE VALUE OF MEDICAL AFFAIRS WHEN ENGAGING IN CROSS-FUNCTIONAL COLLABORATIONS

10:40 am Panel Discussion: What Is the Role of Medical Affairs in the Launch of a Gene Therapy

Synopsis

  • How can medical affairs prepare the market for an imminent launch beyond reactive responses?
  • How should medical affairs promote the distinctive features of a clinical program?
  • How do you keep KOL’s engaged and the gene therapy front of mind in a complaint manner?

11:30 am Integrated Evidence Planning For Cross-Functional Evidence Generation in Gene Therapy

  • Nicole LaMarca Global Medical Director, Data Exploration and Generation Lead-SME Global Medical Affairs, Novartis Gene Therapies

Synopsis

  • Introduce the development of an Integrated Evidence Plan
  • Identify and gain an understanding of common mistakes encountered during the traditional evidence generation approach
  • Recognize and appreciate the evolving and increased stakeholder evidence demands
  • Discuss best practices for IEP development

12:00 pm
Lunch & Networking

DEFINING THE VALUE OF MEDICAL AFFAIRS WHEN ENGAGING IN CROSS-FUNCTIONAL COLLABORATIONS

1:00 pm Field Medical Value Throughout the Drug Lifecycle

Synopsis

  • Discover how Medical Affairs teams are working collaboratively with Clinical Development teams and the approaches being adopted to define clear definition of roles that mitigate a historic ‘territorial’ nature
  • Understand the steps taken to create partnerships with Clinical Operations and Development teams and assess examples of positive working dynamics
  • Learn how best to demonstrate the access Medical Affairs can provide to Clinical teams
  • Identify how platforms are being built to monetize Medical Affairs outputs to successfully demonstrate value

ENHANCING THE VALUE OF MEDICAL AFFAIRS IN A LAUNCH ENVIRONMENT

1:50 pm Uncover How To Demonstrate The Incremental Value of Gene Therapies in a Space Where Other Treatment Options Exist and There Is a Perception of Little Unmet Need

Synopsis

  • Identify how gene therapy developers are disrupting therapeutic areas such as Hemophilia, where non gene therapy treatment options exist and are currently valued
  • Discuss how adopting a co-creation model with physicians and patient advocacy groups increases ‘buy in’ and strengthens the value story

2:20 pm Chairs Closing Remarks

2:30 pm End of Conference